Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin Add-on to Metformin and Pioglitazone in Type 2 Diabetes
NCT01106690Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Hemoglobin A1c at 26 weeks. Started Jun 2010; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01106690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106690.